Patents Assigned to Merck
  • ANTIMALARIAL AGENTS
    Publication number: 20250066379
    Abstract: Provided are methods of treating malaria comprising administration of compounds of Formula (I), or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Application
    Filed: December 5, 2022
    Publication date: February 27, 2025
    Applicants: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical Research, MSD R&D (China) Co., Ltd.
    Inventors: John A. McCauley, Manuel De Lera Ruiz, Zhuyan Guo, Philippe Nantermet, Michael J. Kelly, III, Alvaro Gutierrez Bonet, Lianyun Zhao, Zhiyu Lei, Bin Hu, Dongmei Zhan, Anthony Hodder
  • METHODS AND COMPOSITIONS FOR PURIFYING ADENO ASSOCIATED VIRUS PARTICLES
    Publication number: 20250066743
    Abstract: The present invention relates to methods for purifying adeno-associated virus particles by cation exchange mixed mode chromatography.
    Type: Application
    Filed: March 15, 2023
    Publication date: February 27, 2025
    Applicant: MERCK PATENT GMBH
    Inventors: Bianca EDELMANN, Helena MARIE, Oliver RAMMO, Karen KLEWER
  • Stabilized RSV F proteins and uses thereof
    Patent number: 12234265
    Abstract: The disclosure relates to stable RSV F proteins and immunogenic compositions containing the same, as well as methods of using the immunogenic compositions and compositions comprising the RSV F proteins.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: February 25, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Lan Zhang, Arthur Fridman, Eberhard Durr, Andrew Bett
  • SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20250059220
    Abstract: Provided are novel Substituted Thiophene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R7 are as defined herein, as well as compositions comprising at least one Substituted Thiophene Derivative, and methods of using the Substituted Thiophene Derivatives for treating or preventing cancer in a patient.
    Type: Application
    Filed: December 15, 2022
    Publication date: February 20, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: David A. Candito, Matthew L. Childers, Duane E. DeMong, Christian Fischer, Xavier Fradera, James P. Jewell, Shuhei Kawamura, Ping Liu, Charles S. Yeung, Xiao Mei Zheng, Kaitlyn Marie Logan, Ryan D. Otte, Chunhui Huang, Sebastian E. Schneider
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20250059157
    Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Application
    Filed: October 23, 2024
    Publication date: February 20, 2025
    Applicant: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger
  • Dye-doped liquid-crystal medium comprising polymerizable compounds
    Patent number: 12227688
    Abstract: A liquid-crystal (LC) medium containing one or more dyes and one or more polymerizable compounds, its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in colour LC displays of the PSA (polymer sustained alignment) or SA (self-aligning) mode containing a quantum dot colour filter (QDCF), an LC display of the PSA or SA mode containing the LC medium and containing a QDCF, and to a process of manufacturing the LC display.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: February 18, 2025
    Assignee: Merck Patent GmbH
    Inventors: Hyun-Woo Bae, Jung-Min Lee, Hyun-Jin Yoon, Yong-Kuk Yun
  • Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer
    Patent number: 12227577
    Abstract: The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 antagonist, an ATR inhibitor and a platinating agent.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: February 18, 2025
    Assignee: Merck Patent GMBH
    Inventors: Marat Alimzhanov, Patricia Soulard, Frank Zenke, Heike Dahmen, Astrid Zimmermann, Andreas Schroeder, Keyvan Tadjalli Mehr, Martin Falk
  • Crystalline forms of an NRTTI compound
    Patent number: 12227536
    Abstract: The present disclosure provides novel anhydrate crystalline Forms 1 and 4 of 4?-Ethynyl-2-fluoro-2?-deoxyadenosine and pharmaceutical compositions thereof, each of which may be useful for the inhibition of HIV reverse transcriptase, the treatment or prophylaxis of HIV infection and/or the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: February 18, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Daniel Skomski, Yongchao Su, Wei Xu, Marko Cubrovic, Stephanie Elizabeth Barrett
  • MONOVALENT INTERLEUKIN 12 (IL-12) HETERODIMERIC FC PROTEINS
    Publication number: 20250051434
    Abstract: Monovalent IL-12 heterodimeric Fc proteins that display attenuated potency at the IL-12 receptor compared to wild-type IL-12 and have an extended half-life compared to wild-type IL-12 are described. The monovalent heterodimeric IL-12 heterodimeric Fc proteins comprise a heterodimer comprising an IL-12p35 subunit first Fc domain fusion protein and an IL-p40 subunit second Fc domain fusion protein IL-12 and Fc domains wherein the first and second Fc domains comprise modifications that facilitate heterodimerization of the first Fc domain to the second Fc domain.
    Type: Application
    Filed: August 8, 2024
    Publication date: February 13, 2025
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Mehabaw Getahun Derebe, Ghassan N. Fayad, Veronica M. Juan, Mike Lee, Ji Hea Park, Piyali Saha, Fan Zhang
  • 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20250049814
    Abstract: The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.
    Type: Application
    Filed: October 24, 2024
    Publication date: February 13, 2025
    Applicant: MERCK PATENT GMBH
    Inventors: Anne-Laure BLAYO, Baptiste MANTEAU, Camille AMALRIC, Stanislas MAYER, Stephan SCHANN, Mickaël FER
  • PYRAZOLOPYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES
    Publication number: 20250051341
    Abstract: Provided are novel Pyrazolopyrimidine Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are as defined herein. Also provided are compositions comprising at least one Pyrazolopyrimidine Derivative, and methods of using the Pyrazolopyrimidine Derivatives for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 13, 2022
    Publication date: February 13, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kira A. Armacost, Andrew J. Cooke, Christopher Douglas Cox, Brendan M. Crowley, Marc A. Labroli, Michael A. Plotkin, Izzat T. Raheem, Kelly-Ann S. Schlegel, Anthony W. Shaw, David M. Tellers
  • SILICON PRECURSOR COMPOUND AND PREPARATION METHOD THEREFOR, AND SILICON-CONTAINING THIN FILM PREPARATION METHOD USING SILICON PRECURSOR
    Publication number: 20250051914
    Abstract: A silicon precursor compound according to Formula I as described herein is used to form a silicon-containing thin film having excellent quality. A preparation method therefor, and a silicon-containing thin film preparation method using the silicon precursor compound are also described.
    Type: Application
    Filed: October 25, 2024
    Publication date: February 13, 2025
    Applicant: MERCK PATENT GmbH
    Inventors: Byeong-IL Yang, Hee-Yeon Jeong, Yeong-Ju Seong, Seong-Hak Cheon, Joo-Yong Kim, Young-Hun Byun
  • INSULIN RECEPTOR PARTIAL AGONISTS
    Publication number: 20250051416
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: August 24, 2021
    Publication date: February 13, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Dmitri A. Pissarnitski, Lin Yan
  • Treatment of migraine
    Patent number: 12220408
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Grant
    Filed: July 18, 2024
    Date of Patent: February 11, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Mary Ann Johnson, Leonardo R. Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Jr., Rebecca Nofsinger, Melanie J. Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • Light emitting core and shell nanoparticle
    Patent number: 12221572
    Abstract: A semiconducting light emitting nanoparticle is described having a core and shell structure. The particle has a core and an outer layer or shell. The outer layer covers at least part of the core and contains a metal cation and a divalent anion. Additionally, one or more organic moieties are directly attached to the anion of the outer layer by covalent bond. The divalent anion is Se2?, S2?, Te2?, O2? or a combination thereof. The metal cation can be a monovalent, cation, trivalent, or tetravalent cation. Also, a process for synthesizing the semiconducting light emitting nanoparticle is described.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: February 11, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Elizaveta Kossoy, Shany Neyshtadt, Sanaa Khalil, Alex Rabkin, Jessica Benjamini Ettedgui
  • Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and amino ethyl esters
    Patent number: 12221445
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethyl ester, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to amino acid ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: February 11, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Rudolf Moser, Viola Groehn, Ruth Boehni Stamm, Fritz Blatter, Martin Szelagiewicz
  • PROCESSES FOR THE FORMULATION OF PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN
    Publication number: 20250041428
    Abstract: The present invention provides a number of process improvements related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae to a carrier protein. These processes are serotype specific and include acid hydrolysis, addition of sodium chloride to the reductive amination reaction, and addition of sucrose to dissolve polysaccharides. Polysaccharide-protein conjugates prepared using the processes of the invention can be included in multivalent pneumococcal conjugate vaccines.
    Type: Application
    Filed: October 25, 2024
    Publication date: February 6, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Patrick McHugh, Janelle Konietzko
  • MODEL-BASED ANALYTICAL TOOL FOR BIOREACTORS
    Publication number: 20250043232
    Abstract: Method and system to analyze biomasses in a bioreactor (3) via a computer (2) with a system software (5), the bioreactor (3) having at least one sensor (6) to measure the biomasses and which has a data connection to the computer (2) managed by a data interface provided by the system software (5), wherein the system software (5) provides a data conversion model (8) to analyze real time raw data about permittivity measured by and transmitted from the at least one sensor (6) to the computer (2) to calculate specific cell parameters of cells in the biomasses.
    Type: Application
    Filed: December 1, 2022
    Publication date: February 6, 2025
    Applicant: MERCK PATENT GMBH
    Inventors: Laurent JOURDAINNE, Adele SCHINI, Karine Elise VOLTZ, Bartolomeo DE CANDITIIS
  • BIOMARKERS FOR PREDICTING ELIGIBILITY FOR AN ANTI-ILT4 AND ANTI-PD-1 COMBINATION THERAPY
    Publication number: 20250044295
    Abstract: Disclosed herein are biomarkers that correlate with responses to an anti-ILT4 and anti-PD-1 combination therapy. A biomarker that can differentiate responders from non-responders to this combination therapy can potentially be used to select human subjects who have a higher probability to benefit from such a combination therapy. In one embodiment, a combined positive score (CPS) for PD-L 1 expression in a tumor sample from a human subject is used as a biomarker to differentiate a responder from a non-responder to an anti-ILT4 and anti-PD-1 combination therapy. In another embodiment, a T-cell-inflamed gene expression profile (TcellinfGEP) score is used as a biomarker to differentiate a responder from a non-responder to an anti-ILT4 and anti-PD-1 combination therapy.
    Type: Application
    Filed: December 15, 2022
    Publication date: February 6, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Rachel Allison Altura, Jared Lunceford, Julia F. Markensohn, Leah Suttner, Douglas C. Wilson
  • Liquid crystalline medium and electro-optical device
    Patent number: 12215267
    Abstract: The new media exhibit a ferroelectric nematic phase preferably at ambient temperature. They preferably comprise one or more compounds selected from the group of compounds of formulae IA, IB and IC, in which the variable groups have the meanings indicated in the text and in the claims. Use of the media for providing ferroelectric nematic materials and a method of operation of an electro-optical device are presented. The media may be useful for energy-saving displays and electrical appliances.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: February 4, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Matthias Bremer, Atsutaka Manabe, Martin Kraska